Neurology Live, a clinical neurologists focused media portal has published GN Corporation’s presentation at the MDA on the Clinical trial results of Neu REFIX in Duchenne Muscular Dystrophy
Blog
Neu REFIX Research on Duchenne Muscular Dystrophy to be presented at Muscular Dystrophy Association Conference 2023
GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its […]
Commemoration of World Parkinson’s Day 2023
NICHI BRITE (AFO-202), one of the NICHI GLUCAN brand products for overseas markets, has undergone clinical tri […]
BEES-HAUS method yielding successful cell engraftment to prevent recurrence of urethral stricture confirmed; Manuscript published in Stem Cell Reviews and Reports
Manuscript published in Stem Cell Reviews and Reports
Autologous immune-cell therapy practiced in Japan, helping Vinmec Hospital after technology transfer
Technology transfer on cell therapy to Vietnam by GN Corporation leads to new opportunities
Webiner on “Cell Therapy Approaches for Urethral Stricture” jointly held with Edogawa Hospital
Webiner on Cell Therapy Approaches for Urethral Stricture is held on 16 OCt 2022
Paper on Potential of Beta-Glucan Products to Prevent and Treat Non-Alcoholic Fatty Liver Disease
A look at the potential of beta-glucan for the growing number of non-alcoholic fatty liver diseases
Value addition to Japanese technologies by GN Corp, featured in Government of Japan official website
GNC’s activities are introduced in the Japan Cabinet Office’s site ‘Invest Japan’
A study of Nichi Glucan on children with autism has been published in Research Features Magazine
This is the research on the potential of beta-glucan for autism
Rejuvenating human cartilage cells in the lab, proven by miRNA140 enhancement
A breakthrough achievement on miRNA140 is published in Medicine Innovates